Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
The Goldman Sachs Group, Inc. stock logo
GS
The Goldman Sachs Group
$945.40
-0.3%
$878.61
$582.50
$984.70
$278.90B1.282.29 million shs968,825 shs
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
$988.76
-1.6%
$939.88
$623.78
$1,133.95
$931.15B0.483.18 million shs1.42 million shs
Pfizer Inc. stock logo
PFE
Pfizer
$25.31
-0.1%
$26.98
$22.64
$28.75
$144.22B0.3542.21 million shs22.74 million shs
Health Care Select Sector SPDR Fund stock logo
XLV
Health Care Select Sector SPDR Fund
$145.69
+0.4%
$147.10
$127.96
$160.59
$38.20B0.5812.84 million shs6.09 million shs
Reduce the Risk Cover

Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Click the link to learn more about using beta to protect your portfolio.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
The Goldman Sachs Group, Inc. stock logo
GS
The Goldman Sachs Group
0.00%+1.41%+2.61%+4.90%+53.48%
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
0.00%+6.03%+8.45%-3.36%+32.75%
Pfizer Inc. stock logo
PFE
Pfizer
0.00%-1.32%-8.23%-8.22%+10.88%
Health Care Select Sector SPDR Fund stock logo
XLV
Health Care Select Sector SPDR Fund
0.00%+1.12%-2.49%-7.97%+9.02%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
The Goldman Sachs Group, Inc. stock logo
GS
The Goldman Sachs Group
$945.40
-0.3%
$878.61
$582.50
$984.70
$278.90B1.282.29 million shs968,825 shs
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
$988.76
-1.6%
$939.88
$623.78
$1,133.95
$931.15B0.483.18 million shs1.42 million shs
Pfizer Inc. stock logo
PFE
Pfizer
$25.31
-0.1%
$26.98
$22.64
$28.75
$144.22B0.3542.21 million shs22.74 million shs
Health Care Select Sector SPDR Fund stock logo
XLV
Health Care Select Sector SPDR Fund
$145.69
+0.4%
$147.10
$127.96
$160.59
$38.20B0.5812.84 million shs6.09 million shs
Reduce the Risk Cover

Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Click the link to learn more about using beta to protect your portfolio.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
The Goldman Sachs Group, Inc. stock logo
GS
The Goldman Sachs Group
0.00%+1.41%+2.61%+4.90%+53.48%
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
0.00%+6.03%+8.45%-3.36%+32.75%
Pfizer Inc. stock logo
PFE
Pfizer
0.00%-1.32%-8.23%-8.22%+10.88%
Health Care Select Sector SPDR Fund stock logo
XLV
Health Care Select Sector SPDR Fund
0.00%+1.12%-2.49%-7.97%+9.02%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
The Goldman Sachs Group, Inc. stock logo
GS
The Goldman Sachs Group
2.36
Hold$942.24-0.33% Downside
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
2.87
Moderate Buy$1,218.3323.22% Upside
Pfizer Inc. stock logo
PFE
Pfizer
2.23
Hold$28.8413.98% Upside
Health Care Select Sector SPDR Fund stock logo
XLV
Health Care Select Sector SPDR Fund
2.75
Moderate Buy$145.27-0.29% Downside

Current Analyst Ratings Breakdown

Latest GS, LLY, XLV, and PFE Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
5/14/2026
Pfizer Inc. stock logo
PFE
Pfizer
Reiterated RatingUnderperform$26.00
5/8/2026
The Goldman Sachs Group, Inc. stock logo
GS
The Goldman Sachs Group
DowngradeBuy (B-)Hold (C+)
5/8/2026
The Goldman Sachs Group, Inc. stock logo
GS
The Goldman Sachs Group
Boost Price TargetNeutral$765.00 ➝ $930.00
5/8/2026
The Goldman Sachs Group, Inc. stock logo
GS
The Goldman Sachs Group
UpgradeHold
5/7/2026
The Goldman Sachs Group, Inc. stock logo
GS
The Goldman Sachs Group
Boost Price Target$890.00 ➝ $1,050.00
5/7/2026
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
Boost Price Target$880.00 ➝ $900.00
5/6/2026
Pfizer Inc. stock logo
PFE
Pfizer
UpgradeHold (C-)Hold (C)
5/6/2026
The Goldman Sachs Group, Inc. stock logo
GS
The Goldman Sachs Group
Boost Price Target$930.00 ➝ $940.00
5/5/2026
The Goldman Sachs Group, Inc. stock logo
GS
The Goldman Sachs Group
Boost Price TargetNeutral$891.00 ➝ $930.00
5/5/2026
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
Reiterated RatingBuy$1,183.00
5/4/2026
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
UpgradeBuy (B-)Buy (B)
(Data available from 5/18/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
The Goldman Sachs Group, Inc. stock logo
GS
The Goldman Sachs Group
$125.10B2.23$64.36 per share14.69$366.15 per share2.58
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
$65.18B14.29$24.73 per share39.98$28.07 per share35.22
Pfizer Inc. stock logo
PFE
Pfizer
$62.58B2.30$4.39 per share5.76$15.26 per share1.66
Health Care Select Sector SPDR Fund stock logo
XLV
Health Care Select Sector SPDR Fund
N/AN/AN/AN/AN/AN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
The Goldman Sachs Group, Inc. stock logo
GS
The Goldman Sachs Group
$17.18B$54.7217.2814.371.2214.13%16.53%0.97%7/14/2026 (Estimated)
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
$20.64B$28.1535.1222.351.0934.98%105.77%23.76%8/5/2026 (Estimated)
Pfizer Inc. stock logo
PFE
Pfizer
$7.77B$1.3119.328.85N/A11.83%19.44%8.41%8/4/2026 (Estimated)
Health Care Select Sector SPDR Fund stock logo
XLV
Health Care Select Sector SPDR Fund
N/AN/A21.15N/AN/AN/AN/AN/AN/A

Latest GS, LLY, XLV, and PFE Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/5/2026Q1 2026
Pfizer Inc. stock logo
PFE
Pfizer
$0.7220$0.75+$0.0280$0.47$13.84 billion$14.45 billion
4/30/2026Q1 2026
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
$6.97$8.55+$1.58$8.26$17.82 billion$19.80 billion
4/13/2026Q1 2026
The Goldman Sachs Group, Inc. stock logo
GS
The Goldman Sachs Group
$15.92$17.55+$1.63$17.55$16.66 billion$17.23 billion
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
The Goldman Sachs Group, Inc. stock logo
GS
The Goldman Sachs Group
$18.001.90%+22.87%32.89%13 Years
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
$6.920.70%+15.18%24.58%11 Years
Pfizer Inc. stock logo
PFE
Pfizer
$1.726.80%-13.20%131.30%16 Years
Health Care Select Sector SPDR Fund stock logo
XLV
Health Care Select Sector SPDR Fund
$2.501.72%N/AN/AN/A

Latest GS, LLY, XLV, and PFE Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
4/13/2026
The Goldman Sachs Group, Inc. stock logo
GS
The Goldman Sachs Group
quarterly$4.502.02%6/1/20266/1/20266/29/2026
4/22/2026
Pfizer Inc. stock logo
PFE
Pfizer
quarterly$0.436.71%5/8/20265/8/20266/12/2026
5/4/2026
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
quarterly$1.730.69%5/15/20265/15/20266/10/2026
(Data available from 1/1/2013 forward)
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
The Goldman Sachs Group, Inc. stock logo
GS
The Goldman Sachs Group
2.89
0.63
0.63
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
1.26
1.50
1.10
Pfizer Inc. stock logo
PFE
Pfizer
0.67
1.25
0.94
Health Care Select Sector SPDR Fund stock logo
XLV
Health Care Select Sector SPDR Fund
N/AN/AN/A

Institutional Ownership

CompanyInstitutional Ownership
The Goldman Sachs Group, Inc. stock logo
GS
The Goldman Sachs Group
71.21%
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
82.53%
Pfizer Inc. stock logo
PFE
Pfizer
68.36%
Health Care Select Sector SPDR Fund stock logo
XLV
Health Care Select Sector SPDR Fund
N/A
CompanyEmployeesShares OutstandingFree FloatOptionable
The Goldman Sachs Group, Inc. stock logo
GS
The Goldman Sachs Group
47,400295.01 million293.38 millionOptionable
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
50,000941.74 million940.42 millionOptionable
Pfizer Inc. stock logo
PFE
Pfizer
75,0005.70 billion5.66 billionOptionable
Health Care Select Sector SPDR Fund stock logo
XLV
Health Care Select Sector SPDR Fund
N/A262.11 millionN/ANot Optionable

Recent News About These Companies

Close-up of semiconductor chips and silicon wafer, representing AMD and AI-driven growth in the semiconductor industry.
What Q1 Earnings Could Mean for the S&P 500 Uptrend (XLV)
...

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
The Goldman Sachs Group stock logo

The Goldman Sachs Group NYSE:GS

$945.40 -3.07 (-0.32%)
Closing price 03:59 PM Eastern
Extended Trading
$946.30 +0.90 (+0.10%)
As of 04:03 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

The Goldman Sachs Group, Inc., a financial institution, provides a range of financial services for corporations, financial institutions, governments, and individuals worldwide. It operates through Global Banking & Markets, Asset & Wealth Management, and Platform Solutions segments. The Global Banking & Markets segment provides financial advisory services, including strategic advisory assignments related to mergers and acquisitions, divestitures, corporate defense activities, restructurings, and spin-offs; and relationship lending, and acquisition financing, as well as secured lending, through structured credit and asset-backed lending and involved in financing under securities to resale agreements. This segment also offers client execution activities for cash and derivative instruments; credit and interest rate products; and provision of mortgages, currencies, commodities, and equities related products, as well as underwriting services. The Asset & Wealth Management segment manages assets across various classes, including equity, fixed income, hedge funds, credit funds, private equity, real estate, currencies, and commodities; and provides customized investment advisory solutions, wealth advisory services, personalized financial planning, and private banking services, as well as invests in corporate equity, credit, real estate, and infrastructure assets. The Platform Solutions segment offers credit cards and point-of-sale financing for purchase of goods or services. This segment also provides cash management services, such as deposit-taking and payment solutions for corporate and institutional clients. The Goldman Sachs Group, Inc. was founded in 1869 and is headquartered in New York, New York.

Eli Lilly and Company stock logo

Eli Lilly and Company NYSE:LLY

$988.76 -16.16 (-1.61%)
Closing price 03:59 PM Eastern
Extended Trading
$986.60 -2.16 (-0.22%)
As of 04:03 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provides oncology products, including Alimta, Cyramza, Erbitux, Jaypirca, Retevmo, Tyvyt, and Verzenio. In addition, the company offers Olumiant for rheumatoid arthritis, atopic dermatitis, severe alopecia areata, and COVID-19; Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis; Omvoh for ulcerative colitis; Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Ebglyss for severe atopic dermatitis; and Emgality for migraine prevention and episodic cluster headache. Further, it provides Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. It has collaborations with Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; F. Hoffmann-La Roche Ltd and Genentech, Inc.; Biologics, Inc., AbCellera Biologics Inc.; and Chugai Pharmaceutical Co., Ltd. The company was founded in 1876 and is headquartered in Indianapolis, Indiana.

Pfizer stock logo

Pfizer NYSE:PFE

$25.30 -0.03 (-0.10%)
Closing price 03:59 PM Eastern
Extended Trading
$25.30 -0.01 (-0.04%)
As of 04:04 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands. It also provides medicines and vaccines in various therapeutic areas, such as biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Litfulo, Velsipity, and Cibinqo brands; amyloidosis, hemophilia, endocrine diseases, and sickle cell disease under the Vyndaqel family, Oxbryta, BeneFIX, Somavert, Ngenla, and Genotropin brands; sterile injectable and anti-infective medicines under the Sulperazon, Medrol, Zavicefta, Zithromax, and Panzyga brands; and biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Inlyta, Bosulif, Mektovi, Padcev, Adcetris, Talzenna, Tukysa, Elrexfio, Tivdak, Lorbrena, and Braftovi brands. In addition, the company involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, individual provider offices, retail pharmacies, and integrated delivery systems. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Merck KGaA; and BioNTech SE. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

Health Care Select Sector SPDR Fund stock logo

Health Care Select Sector SPDR Fund NYSEARCA:XLV

$145.69 +0.59 (+0.40%)
Closing price 03:59 PM Eastern
Extended Trading
$145.65 -0.03 (-0.02%)
As of 04:03 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Health Care Select Sector SPDR Fund (the Fund) seeks to closely match the returns and characteristics of the S&P Health Care Select Sector Index (the Index). The companies included in the Index are selected on the basis of general industry classification from a universe of companies defined by the Standard & Poor's 500 Composite Stock Index (S&P 500). The Health Care Select Sector Index includes companies from the industries, such as pharmaceuticals, healthcare providers and services, healthcare equipment and supplies, biotechnology, life sciences tools and services, and healthcare technology. Under normal market conditions, the Fund generally invests substantially all, but at least 95%, of its total assets in the securities comprising the Index. State Street Global Advisors acts as the Fund's investment manager.